Theravance Biopharma, Inc. Interest Expense
Theravance Biopharma, Inc. (TBPH) reported Interest Expense of $629.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-15
- Theravance Biopharma, Inc. interest expense for the quarter ending 2024-03-31 was $629.00K, a 14.36% increase year-over-year.
- Theravance Biopharma, Inc. interest expense for the quarter ending 2023-12-31 was $623.00K, a 13.27% increase year-over-year.
- Theravance Biopharma, Inc. interest expense for the quarter ending 2023-09-30 was $609.00K, a 60.58% decline year-over-year.
- Theravance Biopharma, Inc. interest expense for the quarter ending 2023-06-30 was $568.00K, a 73.42% decline year-over-year.
- Theravance Biopharma, Inc. interest expense for fiscal 2023 was $2.35M, a 63.10% decline from fiscal 2022.
- Theravance Biopharma, Inc. interest expense for fiscal 2022 was $6.37M, a 25.48% decline from fiscal 2021.
- Theravance Biopharma, Inc. interest expense for fiscal 2021 was $8.55M, a 0.00% change from fiscal 2020.
- Theravance Biopharma, Inc. interest expense for fiscal 2020 was $8.55M, a 73.17% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $629.00K 10-Q · filed 2024-05-15 | $1.25M derived: sum of 2 quarters · filed 2024-05-15 | $1.86M derived: sum of 3 quarters · filed 2024-05-15 | $2.43M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2023-12-31 | $623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.23M derived: sum of 2 quarters · filed 2024-03-01 | $1.80M derived: sum of 3 quarters · filed 2024-03-01 | $2.35M 10-K · filed 2024-03-01 | ||||
| 2023-09-30 | $609.00K 10-Q · filed 2023-11-09 | $1.18M derived: sum of 2 quarters · filed 2023-11-09 | $1.73M 10-Q · filed 2023-11-09 | $2.28M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2023-06-30 | $568.00K 10-Q · filed 2023-08-09 | $1.12M 10-Q · filed 2023-08-09 | $1.67M derived: sum of 3 quarters · filed 2024-05-15 | $3.21M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2023-03-31 | $550.00K 10-Q · filed 2024-05-15 | $1.10M derived: sum of 2 quarters · filed 2024-05-15 | $2.65M derived: sum of 3 quarters · filed 2024-05-15 | $4.78M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.10M derived: sum of 2 quarters · filed 2024-03-01 | $4.23M derived: sum of 3 quarters · filed 2024-03-01 | $6.37M 10-K · filed 2024-03-01 | ||||
| 2022-09-30 | $1.54M 10-Q · filed 2023-11-09 | $3.68M derived: sum of 2 quarters · filed 2023-11-09 | $5.82M 10-Q · filed 2023-11-09 | $7.96M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $2.14M 10-Q · filed 2023-08-09 | $11.88M 10-Q · filed 2022-08-08 | $4.27M 10-Q · filed 2023-08-09 | $23.54M 10-Q · filed 2022-08-08 | $6.41M derived: sum of 3 quarters · filed 2023-08-09 | $8.55M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $2.14M 10-Q · filed 2023-05-10 | $11.65M 10-Q · filed 2022-05-06 | $4.27M derived: sum of 2 quarters · filed 2023-05-10 | $6.41M derived: sum of 3 quarters · filed 2023-05-10 | $18.02M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.27M derived: sum of 2 quarters · filed 2023-03-01 | $15.88M derived: sum of 3 quarters · filed 2023-03-01 | $8.55M 10-K · filed 2023-03-01 | $46.89M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $2.14M 10-Q · filed 2022-11-09 | $11.74M 10-Q · filed 2021-11-08 | $13.75M derived: sum of 2 quarters · filed 2022-11-09 | $6.41M 10-Q · filed 2022-11-09 | $35.23M 10-Q · filed 2021-11-08 | $1.26M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $11.61M 10-Q · filed 2022-08-08 | $23.48M 10-Q · filed 2022-08-08 | -$873.00K derived: sum of 3 quarters · filed 2023-03-01 | $10.70M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $11.87M 10-Q · filed 2022-05-06 | -$12.48M derived: sum of 2 quarters · filed 2023-03-01 | -$912.00K derived: sum of 3 quarters · filed 2023-03-01 | $10.48M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$24.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$12.79M derived: sum of 2 quarters · filed 2023-03-01 | -$1.39M derived: sum of 3 quarters · filed 2023-03-01 | $8.55M 10-K · filed 2023-03-01 | $44.59M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $11.57M 10-Q · filed 2021-11-08 | $22.96M derived: sum of 2 quarters · filed 2021-11-08 | $32.91M 10-Q · filed 2021-11-08 | $40.94M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $11.39M 10-Q · filed 2021-08-05 | $21.33M 10-Q · filed 2021-08-05 | $29.37M derived: sum of 3 quarters · filed 2022-02-28 | $37.44M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $9.94M 10-Q · filed 2021-05-06 | $17.98M derived: sum of 2 quarters · filed 2022-02-28 | $26.04M derived: sum of 3 quarters · filed 2022-02-28 | $33.95M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $16.10M derived: sum of 2 quarters · filed 2022-02-28 | $24.00M derived: sum of 3 quarters · filed 2022-02-28 | $31.86M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $8.07M 10-Q · filed 2020-11-09 | $15.97M derived: sum of 2 quarters · filed 2020-11-09 | $23.83M 10-Q · filed 2020-11-09 | $27.90M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $7.90M 10-Q · filed 2020-08-10 | $15.76M 10-Q · filed 2020-08-10 | $19.83M derived: sum of 3 quarters · filed 2021-02-26 | $21.97M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $7.86M 10-Q · filed 2020-05-08 | $11.93M derived: sum of 2 quarters · filed 2021-02-26 | $14.07M derived: sum of 3 quarters · filed 2021-02-26 | $16.20M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $6.21M derived: sum of 2 quarters · filed 2021-02-26 | $8.35M derived: sum of 3 quarters · filed 2021-02-26 | $10.48M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $2.14M 10-Q · filed 2019-11-08 | $4.27M derived: sum of 2 quarters · filed 2019-11-08 | $6.41M 10-Q · filed 2019-11-08 | $8.55M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $2.14M 10-Q · filed 2019-08-05 | $4.27M 10-Q · filed 2019-08-05 | $6.41M derived: sum of 3 quarters · filed 2020-02-27 | $8.55M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $2.14M 10-Q · filed 2019-05-10 | $4.27M derived: sum of 2 quarters · filed 2020-02-27 | $6.41M derived: sum of 3 quarters · filed 2020-02-27 | $8.55M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.27M derived: sum of 2 quarters · filed 2020-02-27 | $6.41M derived: sum of 3 quarters · filed 2020-02-27 | $8.55M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $2.14M 10-Q · filed 2018-11-08 | $4.27M derived: sum of 2 quarters · filed 2018-11-08 | $6.41M 10-Q · filed 2018-11-08 | $7.81M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $2.14M 10-Q · filed 2018-08-02 | $4.27M 10-Q · filed 2018-08-02 | $5.68M derived: sum of 3 quarters · filed 2019-02-28 | $5.68M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | $2.14M 10-Q · filed 2018-05-09 | $3.54M derived: sum of 2 quarters · filed 2019-02-28 | $3.54M derived: sum of 3 quarters · filed 2019-02-28 | $3.54M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.40M derived: sum of 2 quarters · filed 2019-02-28 | $1.40M derived: sum of 3 quarters · filed 2019-02-28 | $1.40M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 | |||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |